CONNECT BIOPHARMA HOLDINGS LIMITED - AMERICAN DEPO

Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference

24 4 2025 09:00:00 提供 Nasdaq GlobeNewswire

Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart

01 4 2025 09:00:00 提供 Nasdaq GlobeNewswire

Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma

31 3 2025 16:05:00 提供 Nasdaq GlobeNewswire

Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update

31 3 2025 09:00:00 提供 Nasdaq GlobeNewswire

Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

28 3 2025 16:05:00 提供 Nasdaq GlobeNewswire

Connect Biopharma to Present at Two Upcoming Investor Conferences

03 3 2025 08:00:01 提供 Nasdaq GlobeNewswire

Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024

10 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

05 9 2024 16:05:00 提供 Nasdaq GlobeNewswire

Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum

01 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

12 6 2024 18:03:08 提供 Nasdaq GlobeNewswire

Connect Biopharma Announces New Leadership and Chair of the Board of Directors

12 6 2024 16:15:00 提供 Nasdaq GlobeNewswire

Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma

22 5 2024 16:05:00 提供 Nasdaq GlobeNewswire

Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma

07 5 2024 06:30:00 提供 Nasdaq GlobeNewswire

Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update

16 4 2024 16:05:00 提供 Nasdaq GlobeNewswire

Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference

19 3 2024 08:30:00 提供 Nasdaq GlobeNewswire

Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors

12 2 2024 16:30:00 提供 Nasdaq GlobeNewswire

Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

12 12 2023 06:00:00 提供 Nasdaq GlobeNewswire

Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

11 12 2023 16:05:21 提供 Nasdaq GlobeNewswire

Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China

21 11 2023 06:03:00 提供 Nasdaq GlobeNewswire

Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

21 11 2023 06:00:00 提供 Nasdaq GlobeNewswire